
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
INSERM U 612, Institut Curie, Laboratoires 110-112, Centre Universitaire, 91405 Orsay, France
Requests for reprints: Vincent Favaudon, INSERM U 612, Institut Curie-Recherche, Laboratoires 110-112, Centre Universitaire, 91405 Orsay Cedex, France. Phone: 33-1-6986-3188; Fax: 33-1-6986-3187. E-mail: vincent.favaudon{at}curie.u-psud.fr
Radiosensitization caused by the poly(ADP-ribose) polymerase (PARP) inhibitor 4-amino-1,8-naphthalimide (ANI) was investigated in 10 asynchronously growing rodent (V79, CHO-Xrs6, CHO-K1, PARP-1+/+ 3T3, and PARP-1/ 3T3) or human (HeLa, MRC5VI, IMR90, M059J, and M059K) cell lines, either repair proficient or defective in DNA-PK (CHO-Xrs6 and M059J) or PARP-1 (PARP-1/ 3T3). Pulse exposure to ANI (1-hour contact) potentiated radiation response in rodent cells except in PARP-1/ 3T3 fibroblasts. In contrast, ANI did not significantly enhance radiation susceptibility in asynchronously dividing human cells; yet, single-strand break rejoining was lengthened by ca. 7-fold in all but mouse PARP-1/ 3T3s. Circumstantial evidence suggested that radiosensitization by ANI occurs in rapidly dividing cells only. Experiments using synchronized HeLa cells consistently showed that ANI-induced radiosensitization is specific of the S phase of the cell cycle and involves stalled replication forks. Under these conditions, prolonged contact with ANI ended in the formation of de novo DNA double-strand breaks hours after irradiation, evoking collision with uncontrolled replication forks of DNA lesions whose repair was impaired by inhibition of the PARP catalytic activity. The data suggest that increased response to radiotherapy by PARP inhibitors may be achieved only in rapidly growing tumors with a high S-phase content. [Mol Cancer Ther 2006;5(3):56474]
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Note: The current address for G. Noël is Centre Paul-Strauss, Service de Radiothérapie, 3 rue de la Porte de l'Hôpital, BP 42, 67065 Strabourg, France.
Received 10/11/05; revised 12/18/05; accepted 1/12/06.
This article has been cited by other articles:
![]() |
C. Godon, F. P. Cordelieres, D. Biard, N. Giocanti, F. Megnin-Chanet, J. Hall, and V. Favaudon PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility Nucleic Acids Res., August 1, 2008; 36(13): 4454 - 4464. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-F. Haince, S. Kozlov, V. L. Dawson, T. M. Dawson, M. J. Hendzel, M. F. Lavin, and G. G. Poirier Ataxia Telangiectasia Mutated (ATM) Signaling Network Is Modulated by a Novel Poly(ADP-ribose)-dependent Pathway in the Early Response to DNA-damaging Agents J. Biol. Chem., June 1, 2007; 282(22): 16441 - 16453. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ratnam and J. A. Low Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology Clin. Cancer Res., March 1, 2007; 13(5): 1383 - 1388. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |